Clinical Colorectal Cancer

Kroger Health Establishes Clinical Trial Site Network to Increase Reach and Access to Research Studies

Retrieved on: 
Martedì, Gennaio 24, 2023
Biomarker, US1, KR, Digital, CDC, Medicine, Cancer, NYSE, Food, Trial of the century, Risk, Colorectal cancer, Doctor of Pharmacy, Health, Bacteria, Woman, Clinical trial, Clinical Colorectal Cancer, Communication, Kroger, Pharmaceutical industry, Nursing

CINCINNATI, Jan. 24, 2023 /PRNewswire/ -- Kroger Health, the healthcare division of The Kroger Co. (NYSE: KR), today announced the establishment of its clinical trial site network in conjunction with pharmaceutical industry sponsors, contract research organizations, and health systems. The announcement comes with Kroger's first trial in active recruitment for colorectal cancer gut and immune health observation.

Key Points: 
  • CINCINNATI, Jan. 24, 2023 /PRNewswire/ -- Kroger Health, the healthcare division of The Kroger Co. (NYSE: KR), today announced the establishment of its clinical trial site network in conjunction with pharmaceutical industry sponsors, contract research organizations, and health systems.
  • In collaboration with Persephone Biosciences, Kroger Health is actively recruiting for the ARGONAUT clinical study ( NCT04638751 ) to identify microbiome-based biomarkers indicative of colorectal cancer.
  • During the next year, Kroger Health plans to enroll additional participants and increase its locations.
  • "This is the first of many clinical trial opportunities that will utilize us as an alternative to the traditional clinical trial and research organization model."

Summit Therapeutics Appoints Experienced Clinical Leader Dr. Alessandra Cesano to its Board of Directors

Retrieved on: 
Giovedì, Novembre 17, 2022
Marketing, COVID-19, EPIX, Doctor of Philosophy, University of Turin, GSK, Clinical Colorectal Cancer, Alessandra, Food, University, Team, Amgen, Knowledge, Patient, MD, Security (finance), Cesano, Food and Drug Administration Amendments Act of 2007, Ridinilazole, Cancer, Self-signed certificate, Biogen, Risk, Panitumumab, Prostate cancer, Quality of life, SMMT, CMO, Coronavirus, Clinical trial, Medical imaging, Pharmaceutical industry

Menlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that Dr. Alessandra Cesano, MD, PhD,has been appointed to its Board of Directors, effective immediately.

Key Points: 
  • Menlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that Dr. Alessandra Cesano, MD, PhD,has been appointed to its Board of Directors, effective immediately.
  • Dr. Cesano compliments our Board of Directors with her decades of extensive experience in the global clinical development of oncology drugs, stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit.
  • Dr. Cesano currently serves on the board of Puma Biotechnology Inc. (NASDAQ: PBYI), a clinical stage oncology company focused on solid tumors.
  • Team Summit assumes full responsibility for stimulating continuous expansion of knowledge, ability, capability, and well-being for all involved stakeholders and highly-valued shareholders.

Richard Kho, PhD, and Murali Gopal, MD, Join Iterative Scopes in Senior Leadership Roles

Retrieved on: 
Mercoledì, Ottobre 13, 2021
Technology, Medical Devices, Audio, Video, Software, Biotechnology, Hardware, Health, Pharmaceutical, Oncology, Komodo, Sentinel, Ross University School of Medicine, Organization, Amgen, Acceleration, MBA, Technology, Eli Lilly, Degenerative disease, BS, Industry, Awareness, University of California, Riverside, Adoption, Toxicology, Growth, Pharmacy, Physician, Doctor of Philosophy, Lists of diseases, IBD, Syneos Health, Decision-making, Clinical Colorectal Cancer, American Psychiatric Association, Pennsylvania State University, Gastroenterology, AI, Therapy, Intelligence, MIT, Medicine, Clinical trial, University of Southern California, Clinic, Patient, Combined internal medicine and psychiatry residency, AbbVie, Research, Company, University, Drug development, KOL, Scope, MD, Biochemistry, Board, Contract field team, Eli Lilly and Company, American, Melanoma, Abbott Laboratories, Management, Pharmaceutical industry

Iterative Scopes is working on an important mission to dramatically improve patient outcomes in the field of gastroenterology through the use of computer vision and AI, said Dr. Kho.

Key Points: 
  • Iterative Scopes is working on an important mission to dramatically improve patient outcomes in the field of gastroenterology through the use of computer vision and AI, said Dr. Kho.
  • The earlier that physicians can correctly detect, diagnose, and treat disease, the better off we are as patients and as a healthcare system.
  • Dr. Richard Khos career has focused on combining data and technology to drive positive changes in healthcare.
  • I am very excited to have joined the brilliant individuals here at Iterative Scopes, Dr. Gopal noted.

Cancer Gene Therapy Daily Service: The Latest Peer-Reviewed Research and Clinical Trials - ResearchAndMarkets.com

Retrieved on: 
Mercoledì, Settembre 23, 2020
Health, Oncology, Clinical trials, Branches of biology, Biology, Articles, RTT, Biotechnology, Gene therapy, Molecular biology, Cancer, Clinical Colorectal Cancer, American Association for Cancer Research

The "Cancer Gene Therapy Daily" newsletter has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cancer Gene Therapy Daily" newsletter has been added to ResearchAndMarkets.com's offering.
  • Cancer Gene Therapy Daily features the latest peer-reviewed research and clinical trials in human gene therapy for cancers.
  • For over 30 years, the analyst has monitored and reported on the world's emerging research and discoveries every day.
  • Their original content is reported from sources of unparalleled depth according to the highest standards of journalism.

Global Colorectal Cancer Epidemiology and Patient Flow Analysis 2018 - Focus on US, Germany, France, Spain, Italy, UK, and Japan

Retrieved on: 
Venerdì, Aprile 20, 2018
Cancer, RTT, Infectious causes of cancer, Colorectal cancer, Epidemiology of cancer, Oncology, Clinical Colorectal Cancer, Prostate cancer

The "Global Colorectal Cancer Epidemiology and Patient Flow Analysis - 2018" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Colorectal Cancer Epidemiology and Patient Flow Analysis - 2018" report has been added to ResearchAndMarkets.com's offering.
  • The research provides insights into Colorectal Cancer epidemiology, Colorectal Cancer diagnosed patients, and Colorectal Cancer treatment rate for US, Japan, and EU5 countries.
  • The research measures key indicators including prevalence of Colorectal Cancer derived from epidemiological analysis, patients diagnosed with Colorectal Cancer, and patients treated with a drug therapy.
  • The research provides estimates and forecasts of Colorectal Cancer prevalence, Colorectal Cancer diagnosis rate, and Colorectal Cancer treatment rate for the period 2017 - 2026.